Tevimbra (tislelizumab-jsgr) / BeOne Medicines - LARVOL DELTA

PD-1/CD20 dual-target therapy in unfit diffuse large B-cell lymphoma: A real-world pilot study (ASH 2025) - "This real-world study explored the efficacy and safety of programmed cell death protein 1 (PD-1) inhibitor (e.g., tislelizumab) combined with CD20 monoclonal antibody (e.g., rituximab) in this population...All patients received PD-1 inhibitor (pembrolizumab 200 mg intravenously every 3 weeks) combined with CD20 monoclonal antibody (rituximab 375 mg/m² intravenously every 3 weeks) at our institution between January 1, 2023, and December 30, 2024...Conclusion PD-1/CD20 dual-target therapy demonstrated promising efficacy (85.7% response rate) and manageable safety in unfit DLBCL, patients, highlighting its potential as a chemotherapy-sparing regimen. Larger prospective studies are warranted to validate these findings."

Clinical • IO biomarker • Real-world • Real-world evidence • B Cell Lymphoma • Colorectal Cancer • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Solid Tumor • PD-L1

Tafasitamab-containing regimens in relapsed/refractory diffuse large B-cell lymphoma: A real-world retrospective case series (ASH 2025) - "Although first-line treatment with R-CHOP achieves remission in a substantial proportion of patients, many ultimately develop relapsed or refractory (R/R) disease...Uncontrolled after 4 prior regimens, she achieved PR with tafasitamab + lenalidomide + radiotherapy + zanubrutinib (maintained through cycle 3), but she had pre-existing pulmonary infection, recurrent infections, and grade 4 neutropenia...Previously treated with ZRD, she received tafasitamab with no TRAEs; treatment was ongoing at analysis, with response unassessed... This real-world series demonstrates that tafa-containing regimens exhibit clinically meaningful activity in extremely frail, heavily pretreated R/R DLBCL patients with poor baseline PS (ECOG ≥2 in 80%). Critically, combinations incorporating radiotherapy or PD-1 inhibition (tislelizumab) yielded significant responses. These novel combinations warrant prospective investigation in high-risk, poor-PS R/R DLBCL populations where effective, tolerable..."

IO biomarker • Real-world • Real-world evidence • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Extranodal Marginal Zone Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukopenia • Lymphoma • Marginal Zone Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Respiratory Diseases • Thrombocytopenia • BCL2 • MYC

Trilaciclib for the prevention of chemotherapy-induced myelosuppression: A systematic review and meta-analysis (ASH 2025) - "Chemotherapy regimens were heterogeneous and included etoposide-platinum (E/P) (either cisplatin or carboplatin) (n=5), gemcitabine/carboplatin (GCb) (n=2), topotecan (n=2), FOLFOXIRI (n=1), and Carboplatin/Paclitaxel/Tislelizumab (n=1)...It also showed a positive impact on progression-free and overall survival, without compromising chemotherapy effectiveness or increasing toxicity. These findings highlight Trilaciclib's potential as a valuable adjunct to chemotherapy in appropriately selected patients."

Retrospective data • Review • Breast Cancer • Colorectal Cancer • Febrile Neutropenia • Infectious Disease • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Small Cell Lung Cancer • Solid Tumor • Thrombocytopenia • Triple Negative Breast Cancer

Smart start with tislelizumab as frontline treatment in advanced‐stage classical Hodgkin lymphoma:a PET-adapted, chemotherapy-sparing phase 2 study (ASH 2025) - P2 | "32 patients were enrolled in the study from August 2021 to July 2023, with one exclude followingpathological review as peripheral T-cell lymphoma. The remaining 31 patients had a median age of32years (range 21-68), including >45year-old 25.8%, male 59.4% (19/31), and stage IV 64.5% (20/31). All 31 patients completed at least two cycles of tislelizumab monotherapy and PET-2 efficacy evaluation.PET-2 CR rate was 32.3% (10/31), the overall response rate (ORR) was 96.8% (30/31), and one patientdeveloped PD (3.6%) during treatment."

Metastases • P2 data • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Peripheral T-cell Lymphoma

Clinical outcomes and safety of tislelizumab maintenance therapy following autologous stem cell transplantation in patients with relapsed or refractory diffuse large b-cell lymphoma (ASH 2025) - P3 | "Maintenance therapy with tislelizumab after ASCT improves progression-free survival inpatients with R/R DLBCL and demonstrates a favorable safety profile."

Clinical • Clinical data • B Cell Lymphoma • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation

Clinical activity and immune correlates of glofitamab combined with tislelizumab in relapsed/refractory follicular lymphoma: A translational study (ASH 2025) - "We present the first clinical translation of glofitamab combined with tislelizumab (anti-PD-1) inthis high-risk population.MethodsIn this single-center retrospective study (Feb 2024-May 2025), 12 consecutive R/R FL patients receiveda fixed-duration regimen: Cycle 1: Obinutuzumab 1,000mg (Day 1, CRS prophylaxis) followed byglofitamab step-up dosing (2.5mg→10mg→30mg on Day 8/15/22). ConclusionGlofitamab plus tislelizumab demonstrated transformative clinical activity in ultra-high-risk R/R FL,achieving 100% ORR and 83.3% CR with durable MRD-negative remissions in a population uniformlyrefractory to anti-CD20 therapy. The regimen's exceptional safety profile (no high-grade immune toxicity)and predictive role of CREBBP/KMT2D alterations support this fixed-duration, chemotherapy-freestrategy as a paradigm shift, representing the first clinical validation of synergistic PD-1 blockade with T-cell-engaging bispecifics in FL."

Clinical • IO biomarker • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • CREBBP • KMT2D • TNFRSF14

Trial in progress: Treatment of CNS lymphoma with zanubrutinib and tislelizumab: A phase ib/II investigator-initiated study (ASH 2025) - P1/2 | "Futility analysis occursafter 12 patients have been recruited with assessment of the primary endpoint with futility reached if theORR is <50%. Kaplan-Meier analysis is used for survival probabilities."

IO biomarker • P1/2 data • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • T Cell Non-Hodgkin Lymphoma • CD79B • MYD88 • PD-L2

Tislelizumab combined with zanubrutinib and high-dose methotrexate in newly diagnosed primary central nervous system DLBCL: A phase 2 study (ASH 2025) - P2 | "The TZM regimen markedly enhanced the survival prognosis of patients with PCNS-DLBCLand demonstrated favorable treatment safety."

IO biomarker • P2 data • Agranulocytosis • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Granulocytopenia • Hepatology • Infectious Disease • Liver Failure • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Renal Disease • B2M • PD-L1 • TP53

Timed PD-1 blockade synergizes with IL-7/CCL19 armoring to reverse CAR-T exhaustion in PD-L1-high large B-cell lymphoma (ASH 2025) - P1 | "In this phase I trial(NCT04381741), we integrated temporally guided PD-1 blockade (tislelizumab from day 30) with 7×19CAR-T therapy in 20 patients with R/R LBCL...In addition, PD-1 blockade furtherimproved the efficacy of CAR-T cells by relieving the negative regulation of the PD-L1 signaling axis. Insummary, the efficacy of this combined strategy in patients with R/R LBCL was significantly better thanthat of traditional CAR-T therapy, providing a new model for future multi-target immunotherapy."

IO biomarker • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • CCL19 • CD8 • CTLA4 • HAVCR2 • IL7 • LAG3 • PD-L1 • TIGIT

Pre-existing cytotoxic capacity of CD8+ and CD4+ T cells is a hallmark of richter transformation and favors response to anti-PD-1 therapy (ASH 2025) - "To confirm the relevance of our results to human RT, weexamined pre-treatment lymph node (LN) biopsies from 4 patients [2R, 1 partial responder (PR), and 1NR] enrolled in the phase II RT1 clinical trial using the anti-PD-1 agent tislelizumab combined with the BTKinhibitor zanubrutinib by spatial transcriptomics (Visium HD, 10X genomics). We are currentlyvalidating this effect in additional human samples from the RT1 clinical trial using multipleximmunofluorescence staining, and investigating molecular pathways associated with these differencesbetween responders and non-responders. We foresee that these insights into determinants of responsein RT may also be relevant for other lymphomas and for other RT immunotherapies."

IO biomarker • Tumor mutational burden • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Richter's Syndrome • CD4 • CD8 • CXCL9 • GZMB • IFNG • IL2 • TMB • TNFA

Correlates of response to combined checkpoint and BTK inhibition for treatment of richter transformation: Extended follow-up from the prospective RT1 trial (ASH 2025) - "ConclusionWith extended follow-up, over 60% of pts of the efficacy population were alive at 2 years, and durableresponses to tislelizumab plus zanubrutinib lasting beyond 3 years were observed. A distinct RT geneexpression signature was associated with response, potentially enabling identification of pts most likelyto benefit from combined checkpoint and BTK inhibition in RT."

Clinical • IO biomarker • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Richter's Syndrome • HSPD1 • IGH • NOP56 • PD-L1 • PLCG2 • TRAF1

Invited Discussant – Asian perspectives on Phase III study of ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer (HARMONi-6) (ESMO Asia 2025) - No abstract available

Clinical • Metastases • P3 data • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Phase III study of ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer (HARMONi-6) (ESMO Asia 2025) - No abstract available

Clinical • Metastases • P3 data • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Efficacy and safety of disitamab vedotin (DV) combined with tislelizumab as adjuvant therapy after radical surgery for patients with HER2-expression upper tract urothelial carcinoma (UTUC): A single-arm, prospective, phase II study (ESMO Asia 2025) - P=N/A | "The DV/tislelizumab combination demonstrated promising preliminary efficacy and a manageable safety profile as adjuvant therapy in patients with HER2-expression UTUC."

Clinical • P2 data • Surgery • Oncology • Solid Tumor • Urothelial Cancer • HER-2

Real-world safety and efficacy of first-line tislelizumab plus chemotherapy for extensive-stage small cell lung cancer: A multi-institutional analysis (ESMO Asia 2025) - "We present a real-world study conducted in multiple tertiary hospitals in China, evaluating the efficacy and safety of Tislelizumab combined with chemotherapy in the first-line treatment of ES-SCLC. Patients with ES-SCLC who received cisplatin/carboplatin and etoposide with Tislelizumab as 1st-line therapy were included at 8 centers. The real-world data demonstrated that first-line immunochemotherapy for ES-SCLC has promising efficacy and acceptable safety. Moreover, it was observed that additional thoracic radiotherapy can achieve better progression-free survival, which warrants further exploration."

Clinical • Real-world • Real-world evidence • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Survival benefits of immune checkpoint inhibitor plus chemotherapy as first-line treatment for squamous non-small cell lung cancer in the Chinese national medical insurance list: A Bayesian network meta-analysis (ESMO Asia 2025) - "Considering the PFS and OS benefits of camrelizumab plus chemotherapy as first-line treatment for sqNSCLC, it may be regarded as a preferred therapeutic option."

Checkpoint inhibition • Reimbursement • Retrospective data • US reimbursement • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Associations between patient-reported outcomes (PROs) and progression-free survival (PFS) in patients with extensive-stage small cell lung cancer (ES-SCLC): Results from the RATIONALE-312 trial (ESMO Asia 2025) - P3 | "This study explored whether patient-reported, disease-specific symptoms are prognostic of PFS in patients with first-line (1L) ES-SCLC from the RATIONALE-312 trial. 433 patients (n=216 tislelizumab + chemo [T+C]; n=217 placebo + chemo [P+C]) were analyzed using the EORTC-QLQ-C30 and lung cancer-specific QLQ-LC13 instruments...JMs were adjusted for ECOG Performance status (0 vs 1), brain metastasis, and investigator-chosen chemotherapy (cisplatin vs carboplatin). In the LMM, T+C was associated with significantly lower symptom deterioration for QLQ-LC13 chest pain (P=0.0158) compared to P+C... T+C was associated with lower chest pain and a reduced disease progression in patients with ES-SCLC compared to P+C. RS-D in physical functioning was a leading prognostic indicator for risk of disease progression. These findings suggest that patient-reported symptoms and functioning are directly linked to PFS and are important prognostic factors in the treatment of 1L ES-SCLC..."

Clinical • Patient reported outcomes • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Phase II study of tislelizumab in combination with Chidamide in advanced non-small cell lung cancer (NSCLC): 3-year follow-up data update (ESMO Asia 2025) - "The study demonstrated excellent clinical benefit of HDAC inhibitors in combination with PD-1 antibodies in advanced NSCLC with a manageable safety profile."

Combination therapy • IO biomarker • Metastases • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD8

Tislelizumab (TIS) treatment beyond progression in advanced or metastatic non-squamous (nsq) NSCLC after 1L chemoimmunotherapy: Results from randomized, phase 3 RATIONALE-304 study (ESMO Asia 2025) - P3 | "This post hoc analysis suggests a sustained clinical benefit with manageable safety of continued TIS after progression on 1L TIS +chemo in advanced nsq-NSCLC pts, warranting further verification in a larger dataset. Pts with PD-L1 ≥1% expression and response to 1L treatment were shown to have longer post-PD OS, suggesting a sub-population for further investigation of clinical benefit."

Clinical • IO biomarker • Metastases • P3 data • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Tislelizumab plus standard chemotherapy as first-line treatment in advanced thymic epithelial tumors (TETs): A prospective, single-arm trial (ESMO Asia 2025) - P=N/A | "Patients with thymoma or thymic carcinoma will receive tislelizumab combination with standard chemotherapy: thymoma patients receive cisplatin 50mg/m2, liposomal doxorubicin 30mg/m2, and cyclophosphamide 500mg/m2 on day 1; thymic carcinoma patients receive paclitaxel 175mg/m2 and carboplatin AUC5 on day 1. Primary outcome measures will be the overall response rate (ORR) and progression-free survival (PFS). Secondary measures will explore overall survival (OS), duration of response (DOR), disease control rate (DCR) and safety."

Clinical • Metastases • Oncology • Solid Tumor • Thymic Carcinoma • Thymic Epithelial Tumor • Thymoma • Thymus Cancer

TitAN: A prospective, single-arm, phase II study of tislelizumab combined with anlotinib and nab-paclitaxel as neoadjuvant therapy for resectable stage III non-small cell lung cancer (ESMO Asia 2025) - P2 | "Primary endpoint: pathological complete response (pCR) rate. Secondary endpoints: major pathologic response (MPR), R0 resection rate, event-free survival (EFS), overall survival (OS), and safety (CTCAE v5.0)."

Clinical • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

CONCEPT: A phase II study of cryoablation combined with tislelizumab and chemotherapy as neoadjuvant treatment, followed by adjuvant Tislelizumab therapy in resectable stage II-IIIB non-small cell lung cancer (ESMO Asia 2025) - P2 | "The primary endpoint is pCR rate. Secondary endpoints include overall response rate, radiological downstaging rate, major pathological response rate, EFS, overall survival, safety and quality of life."

Clinical • IO biomarker • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR

Comparative efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer (ESMO Asia 2025) - "Predominant ICIs were sintilimab (31%) and tislelizumab (30%). We propose and validate the novel NIHRI prognostic tool. The integrated nomogram provides a non-invasive, cost-effective method for quantitative prognosis prediction in NSCLC immunotherapy, facilitating personalized clinical decision-making."

Checkpoint inhibition • Clinical • IO biomarker • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Treatment patterns and clinical outcomes of stage II-III NSCLC patients receiving perioperative immunochemotherapy: A real-world study (ESMO Asia 2025) - "Immunotherapy agents included tislelizumab (68.0%), pembrolizumab (12.0%), and other ICIs (20.0%). In real-world settings, perioperative immunotherapy has been shown to significantly enhance the pathological response rate and deliver superior survival outcomes compared to historical data from chemotherapy alone."

Clinical • Clinical data • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

Update results of tislelizumab combined with chemotherapy or radiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (TINES): A randomized, open, phase II study (ESMO Asia 2025) - "Arm A received tislelizumab (200 mg on day 1), paclitaxel (150 mg/m2 on day 1) and cisplatin (75 mg/m2 on day 1) once every 3 weeks for 3 cycles, and arm B received radiotherapy with 41.4 Gy in 23 fractions combined with tislelizumab 3 cycles. Tislelizumab combined with either chemotherapy or radiotherapy demonstrates promising efficacy as neoadjuvant treatment for resectable ESCC, particularly showing higher pCR rates in combination with radiotherapy. Further studies are warranted to confirm these findings and survival benefits."

Clinical • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma